The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta‐Analysis
Pooled result · SF-36v2 Physical FunctioningResult — go to the resultMean difference 1.71 points 95% CI 1.07–2.35Authors' conclusion
Semaglutide statistically improves patient-reported outcomes, but average functional gains are modest and should be communicated cautiously.
Study context
- Population
- Adults with overweight or obesity in randomised placebo-controlled trials reporting SF-36v2 or IWQOL-Lite-CT outcomes
- Participants
- 4,182 adults4 STEP trials
- Comparison
- Once-weekly subcutaneous semaglutide 2.4 mg vs placebo
- Outcome
- SF-36v2 Physical Functioning
Methodological detailsprospectively registered, placebo-controlled trials
- Prospectively registered
- Placebo-controlled trials
Pooled result
As reported in the abstract
Mean difference
1.71 points
95% CI 1.07–2.35
Semaglutidevs Placebo
mean difference 1.71 points (95% CI 1.07–2.35)
- Heterogeneity moderate, I 2
- 52.8%
Further pooled results
IWQOL-Lite-CT outcomes
- Trials reporting IWQOL-Lite-CT
- Two trials, 2768 participants
- Effects larger without T2D, smaller with T2D; both below published thresholds
Original publication
The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta‐Analysis. Diabetes Obes Metab. Published 15 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →